Inhibrx Biosciences (INBX) Stock Price & Analysis

INBX$83.30-4.45 -5.07%
BiotechnologyGrowth Stock
Compare
Market cap$1.23BEnterprise value$1.03BRevenue (TTM)$2.00MMarket position—

Score

69
Bullish
Value
49
Quality
58
Growth
100

AI Analysis

Snapshot

Inhibrx Biosciences is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 69/100) in Biotechnology. Under the hood: revenue compounding ~148% annually over recent years. Street targets still imply ~242% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

49
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

58
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Inhibrx Biosciences Inc. (INBX) last printed $83.30. Equity value is $1.23B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$6.67M$8.39M$8.6M$9.09M$12.81M$7.12M$2.19M$1.8M$200,000.00$1.3M

About

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences (INBX) Stock Price & Analysis

INBX price $83.30 -4.45 -5.07%

Ticker
INBX
Price
$83.30
Change
-4.45 -5.07%
Market cap
$1.23B
Forward P/E
27.58
Dividend yield
0.00%
Beta
4.04
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
69
Value
49
Quality
58
Growth
100

Stocklytics score rationale: value 49, quality 58, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener